The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Open accessAbstract
BACKGROUND: The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) has been the subject of much controversy. Major international guidelines recommend selective use of ICS. Recently published meta-analyses have reported conflicting findings on the effects of inhaled steroid therapy in COPD. OBJECTIVES: To determine the efficacy and safety of inhaled corticosteroids in stable patients with COPD, in terms of objective and subjective outcomes. SEARCH METHODS: A pre-defined search strategy was used to search the Cochrane Airways Group Specialised Register for relevant literature. Searches are current as of July 2011. SELECTION CRITERIA: We included randomised trials comparing any dose of any type of inhaled steroid with a placebo control in patients with COPD. Acute bronchodilator reversibility to short-term beta(2)-agonists and bronchial hyper-responsiveness were not exclusion criteria. The a priori primary outcome was change in lung function. We also analysed data on mortality, exacerbations, quality of life and symptoms, rescue bronchodilator use, exercise capacity, biomarkers and safety. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data. We contacted study authors for additional information. We collected adverse effects information from the trials. MAIN RESULTS: Fifty-five primary studies with 16,154 participants met the inclusion criteria. Long-term use of ICS (more than six months) did not consistently reduce the rate of decline in forced expiratory volume in one second (FEV(1)) in COPD patients (generic inverse variance analysis: mean difference (MD) 5.80 mL/year with ICS over placebo, 95% confidence interval (CI) -0.28 to 11.88, 2333 participants; pooled means analysis: 6.88 mL/year, 95% CI 1.80 to 11.96, 4823 participants), although one major trial demonstrated a statistically significant difference. There was no statistically significant effect on mortality in COPD patients (odds ratio (OR) 0.98, 95% CI 0.83 to 1.16, 8390 participants). Long-term use of ICS reduced the mean rate of exacerbations in those studies where pooling of data was possible (generic inverse variance analysis: MD -0.26 exacerbations per patient per year, 95% CI -0.37 to -0.14, 2586 participants; pooled means analysis: MD -0.19 exacerbations per patient per year, 95% CI -0.30 to -0.08, 2253 participants). ICS slowed the rate of decline in quality of life, as measured by the St George's Respiratory Questionnaire (MD -1.22 units/year, 95% CI -1.83 to -0.60, 2507 participants). Response to ICS was not predicted by oral steroid response, bronchodilator reversibility or bronchial hyper-responsiveness in COPD patients. There was an increased risk of oropharyngeal candidiasis (OR 2.65, 95% CI 2.03 to 3.46, 5586 participants) and hoarseness. In the long-term studies, the rate of pneumonia was increased in the ICS group compared to placebo, in studies that reported pneumonia as an adverse event (OR 1.56, 95% CI 1.30 to 1.86, 6235 participants). The long-term studies that measured bone effects generally showed no major effect on fractures and bone mineral density over three years. AUTHORS' CONCLUSIONS: Patients and clinicians should balance the potential benefits of inhaled steroids in COPD (reduced rate of exacerbations, reduced rate of decline in quality of life and possibly reduced rate of decline in FEV(1)) against the potential side effects (oropharyngeal candidiasis and hoarseness, and risk of pneumonia).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Celli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A., Chavannes, N., Dillard, T., Fahy, B., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,421
Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease
Celli, B. R., Snider, G. L., Heffner, J. E., Tiep, B. L., Ziment, I., Make, B. J., Braman, S. S., Olsen, G. N., & D, Y. Y. P. M. (1995) · Cited by 3,506
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
Chronic Obstructive Pulmonary Disease
(2018) · Questions for the Final FFICM Structured Oral Examination · doi:10.1017/9781108233712.025 · Cited by 2,689
The natural history of chronic airflow obstruction.
Fletcher, C., & Peto, R. (1977) · BMJ · doi:10.1136/bmj.1.6077.1645 · Cited by 2,370
Cited by
Spruit, M. A., Singh, S. J., Garvey, C., ZuWallack, R., Nici, L., Rochester, C., Hill, K., Holland, A. E., Lareau, S. C., Man, W. D.-C., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1634st · Cited by 3,938
Glucocorticoid resistance in inflammatory diseases
Barnes, P. J., & Adcock, I. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60326-3 · Cited by 983
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.1564 · Cited by 694
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Complex chronic comorbidities of COPD
Fabbri, L. M., Luppi, F., Beghé, B., & Rabe, K. F. (2008) · European Respiratory Journal · doi:10.1183/09031936.00114307 · Cited by 660
Self-management education for patients with chronic obstructive pulmonary disease
Effing, T., Monninkhof, E. E., van der Valk, P. P. D. L. P. M., Zielhuis, G. G., Walters, E. H., van der Palen, J. J., & Zwerink, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002990.pub2 · Cited by 536
Glucocorticosteroids: current and future directions
Barnes, P. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01199.x · Cited by 533
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Bowerman, K. L., Rehman, S. F., Vaughan, A., Lachner, N., Budden, K. F., Kim, R. Y., Wood, D. L. A., Gellatly, S. L., Shukla, S. D., Wood, L. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19701-0 · Cited by 425
Self-citationMolecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
Medication adherence issues in patients treated for COPD
Restrepo, R. (2008) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s3036 · Cited by 407
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Kew, K. M., & Seniukovich, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010115.pub2 · Cited by 398
McKenzie, D. K., & Frith, P. A. (2003) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05213.x · Cited by 369
Drummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J., & Fan, E. (2008) · JAMA · doi:10.1001/jama.2008.717 · Cited by 364
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease
George, L., & Brightling, C. E. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609251 · Cited by 326
Role of HDAC2 in the Pathophysiology of COPD
Barnes, P. J. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163257 · Cited by 318
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
Halpin, D. M. G., Singh, D., & Hadfield, R. M. (2020) · European Respiratory Journal · doi:10.1183/13993003.01009-2020 · Cited by 310
Vogelmeier, C. F., Criner, G. J., Martínez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.02.001 · Cited by 309
Prevention of Acute Exacerbations of COPD
Criner, G. J., Bourbeau, J., Diekemper, R. L., Ouellette, D. R., Goodridge, D., Hernandez, P., Curren, K., Balter, M. S., Bhutani, M., Camp, P. G., et al. (2015) · Chest · doi:10.1378/chest.14-1676 · Cited by 288
Management of bronchiectasis in adults
Chalmers, J. D., Aliberti, S., & Blasi, F. (2015) · European Respiratory Journal · doi:10.1183/09031936.00119114 · Cited by 286
Barnes, P. J. (2010) · Pharmaceuticals · doi:10.3390/ph3030514 · Cited by 277
Nannini, L. J., Poole, P., Milan, S. J., Holmes, R., & Normansell, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794.pub4 · Cited by 274
Guidelines for the diagnosis, prevention and management of osteoporosis
Rossini, M., Adami, S., Bertoldo, F., Diacinti, D., Gatti, D., Giannini, S., Giusti, A., Malavolta, N., Minisola, S., Osella, G., et al. (2016) · Reumatismo · doi:10.4081/reumatismo.2016.870 · Cited by 272
Loke, Y. K., Cavallazzi, R., & Singh, S. (2011) · Thorax · doi:10.1136/thx.2011.160028 · Cited by 267
Quantification of risk factors for herpes zoster: population based case-control study
Forbes, H. J., Bhaskaran, K., Thomas, S. L., Smeeth, L., Clayton, T., & Langan, S. M. (2014) · BMJ · doi:10.1136/bmj.g2911 · Cited by 267
Nannini, L. J., Lasserson, T. J., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006829.pub2 · Cited by 264
Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Kruis, A. L., Smidt, N., Assendelft, W. J., Gussekloo, J., Boland, M. R., Rutten-van Mölken, M., & Chavannes, N. H. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009437.pub2 · Cited by 259
Bewley, M. A., Belchamber, K. B. R., Chana, K. K., Budd, R. C., Donaldson, G., Wedzicha, J. A., Brightling, C. E., Kilty, I., Donnelly, L. E., Barnes, P. J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163139 · Cited by 64
Metadata
- Authors
- Yang, I. A., Clarke, M. S., Sim, E. H., & Fong, K. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-07-11
- Volume
- 2016
- Issue
- 8
- Pages
- CD002991-CD002991
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1983772324
- Cited by
- 523
- References
- 159
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.